Another vaccine for HLA-A24 positive patients was developed by immunizing HLA-A24 restricted Survivin peptide 2B80–88 which induced peptide specific CTL response in urothelial [104], oral [105], colorectal [106] and breast cancer [107] patients with no adverse effects. This evidence concerns the gene BIRC5 and breast carcinoma.